


Investor Presentation

June 2024

NASDAQ: STAA



Forward Looking Statements

All statements that are not statements of historical fact are forward-looking statements, including statements about any of the following: any financial projections, anticipated financial results, estimates and outlook (including as to net sales, Adjusted EBITDA, and Adjusted EBITDA per diluted share), plans, strategies, and objectives of management for 2024 and beyond or prospects for achieving such plans, expectations for sales, revenue, margin, expenses or earnings, and any statements of assumptions underlying any of the foregoing, including those relating to financial performance in the upcoming quarter, fiscal year 2024 and beyond.

Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include risks and uncertainties related to global economic conditions, as well as the factors set forth in the Company's Annual Report on Form 10-K for the year ended December 29, 2023 under the caption "Risk Factors," which is on file with the Securities and Exchange Commission and available in the "Investor Information" section of the Company's website, www.staar.com, under the heading "SEC Filings."

We disclaim any intention or obligation to update or revise any financial projections or forward-looking statement due to new information or events. These statements are based on expectations and assumptions as of the date of this presentation and are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those described in the forward-looking statements. The risks and uncertainties include the following: global economic conditions; the impact of COVID-19; the discretion of regulatory agencies to approve or reject existing, new or improved products, or to require additional actions before or after approval, or to take enforcement action; international conflicts, trade disputes and substantial dependence on demand from Asia; and the willingness of surgeons and patients to adopt a new or improved product and procedure.

We intend to use our website as a means of disclosing material non-public information and for complying with our disclosure obligations under Regulation FD. Such disclosures will be included on our website in the 'Investor Relations' sections. Accordingly, investors should monitor such portions of our website, in addition to following our presentations, SEC filings and public conference calls and webcasts.

Non-GAAP Financial Information

To supplement the Company's financial measures prepared in accordance with U.S. generally accepted accounting principles (GAAP), this presentation and the accompanying tables include certain non-GAAP financial measures, including Adjusted EBITDA. Management uses these non-GAAP financial measures in its evaluation of Company operating performance and believes investors will find them useful in evaluating the Company's operating performance, including cash flow generation, and in analyzing period-to-period financial performance of core business operations and underlying business trends. Non-GAAP financial measures are in addition to, not a substitute for, or superior to, measures of financial performance prepared in accordance with GAAP.

EBITDA is a non-GAAP financial measure, which is calculated by adding interest income and expense, net; provision for income taxes; and depreciation and amortization to net income. In calculating Adjusted EBITDA and Adjusted EBITDA per diluted share, the Company further adjusts for stock-based compensation expense. As stock-based compensation is a non-cash expense that can vary significantly based on the timing, size and nature of awards granted, the Company believes that the exclusion of stock-based compensation expense can assist investors in comparisons of Company operating results with other peer companies because (i) the amount of such expense in any specific period may not directly correlate to the underlying performance of our business operations and (ii) such expense can vary significantly between periods as a result of the timing of grants of new stock-based awards, including inducement grants in connection with hiring. Additionally, the Company believes that excluding stock-based compensation from Adjusted EBITDA and Adjusted EBITDA per diluted share assists management and investors in making meaningful comparisons between the Company's operating performance and the operating performance of other companies that may use different forms of employee compensation or different valuation methodologies for their stock-based compensation. Investors should note that stock-based compensation is a key incentive offered to employees whose efforts contributed to the operating results in the periods presented and are expected to contribute to operating results in future periods. Investors should also note that such expenses will recur in the future.

In the appendix to this presentation, the Company has included a reconciliation of Adjusted EBITDA and Adjusted EBITDA per diluted share to net income and net income per diluted share, the most directly comparable GAAP financial measure. The Company has also provided a reconciliation of forward-looking Adjusted EBITDA and Adjusted EBITDA per diluted share to net income and net income per diluted share. This represents forward-looking information, and actual results may vary. Please see the risks and assumptions referred to in the Forward Looking Statements section of this presentation.

Why Invest?



**STAAR Surgical is
Ushering in the Next
Generation of Vision
Correction with EVO ICL™**


The Global Myopia Epidemic Means Our Market Opportunity Is Significant




Today: **Every third person** in the world



2050: **Every other person** in the world *



Normal



Myopia

Key Factors with Myopia




Genetic Predisposition



Environmental Factors


MYOPIA

STAAR EVO ICL's near and long-term market opportunity remains exciting and vast, despite any transient noise (previously COVID and now macroeconomic headwinds associated with a normal business cycle). Myopia is a global pandemic with no known cure.



Billions of People

■ Myopia ■ High Myopia



*BHVI, adapted from Holden et al. 2016 Ophthalmology. 36% of studies defined high myopia as -6.0D or more. 05

STAAR / We Are Building Prowess + Momentum to Realize Our Market Opportunity



In fiscal 2023, we delivered our sixth straight year of sales growth and profitability. Our cash-generative business model and strong balance sheet allow STAAR the flexibility to make a myriad of investment and capital allocation decisions designed to advance EVO ICL™, our state-of-the-art lens-based vision correction technology, and create shareholder value.

FISCAL YEAR 2023 REPORTED ON FEBRUARY 26, 2024

\$322.4 M

Net Sales

18%

ICL Sales Growth

19%

ICL Unit Growth

78.4%

Gross Margin

8.8%

Operating Margin



\$232.4 M

Cash, cash equivalents and investments available for sale at Dec. 29, 2023

\$21.3 M

GAAP Net Income

\$56.7 M

Adjusted EBITDA

\$1.15

Adjusted EBITDA per diluted share

OUTLOOK

Fiscal 2024 Outlook

\$335 M to \$340 M

Net Sales

~\$36 M

Adjusted EBITDA

~\$0.70

Adjusted EBITDA per diluted share

Vision 2026 Outlook

\$500 M to \$550 M

Net Sales


STAAR / Our Sales Outlook Is for a Strong Trajectory of Growth

VISION 2026

3-Year Sales CAGR (Fiscal 2024-2026)




Fiscal 2024 ICL Growth *



Sales Opportunities and Hurdles

Pace of EVO ICL adoption down the diopter curve, e.g., increasing utilization of EVO ICL -6D to -8D and above for refractive vision correction.



Country mix (Direct vs. Hybrid/Distributor)

Success of U.S. market building initiatives

Success of initiatives in other markets globally

Macroeconomic environment

First Quarter 2024 Results



Our first quarter results illustrate the impact of our commercial focus, which is driving continued market adoption and share gains of our EVO ICL. Our strategic investments in people and processes in recent quarters are now bearing fruit. We are very pleased by the quickening pace of our momentum to start 2024, marked by several significant business milestones, including today's announcement of the largest-ever practice commitment to EVO ICL in the U.S.

1Q24 EARNINGS REPORT ON MAY 7, 2024

<p>\$77.4 M Net Sales</p>	<p>9% Global ICL Sales Growth</p>	<p>9% APAC</p>	<p>11% EMEA</p>	<p>12% Americas</p>
--------------------------------------	--	--------------------	---------------------	-------------------------

<p>78.9% Gross Margin</p>	<p>(2.9%) Operating Margin</p>
--------------------------------------	---

<p>(\$3.3 M) GAAP Loss</p>	<p>\$5.3 M Adjusted EBITDA</p>	<p>\$0.11 Adjusted EBITDA per diluted share</p>
---------------------------------------	---	--



\$252.1 M

Cash, cash equivalents and investments available for sale at Mar 29, 2024

OUTLOOK

Fiscal 2024 Outlook			
<p>\$335 M to \$340 M Net Sales</p>	<p>~\$39 M* Adjusted EBITDA</p>	<p>~\$0.75* Adjusted EBITDA per diluted share</p>	<p>* Compares to prior outlook of Adjusted EBITDA of approximately \$36 million and Adjusted EBITDA per diluted share of ~ \$0.70.</p>

First Quarter 2024 & Recent Business Highlights

Enhanced commercial focus is yielding positive results



Our APAC, EMEA, Americas regions generated ICL sales growth of 9%, 11% and 12%, respectively in the first quarter vs. fiscal year outlook of 7%, flat and 10%, respectively



Generated 21% sequential sales growth in the U.S., achieving record quarterly U.S. ICL sales of \$5 million



On May 7, 2024, STAAR announced the largest commitment ever to EVO ICL in the U.S. – a strategic agreement with Dr. Robert Lin and IQ Laser Vision as part of our **U.S. Highway 93** go-to-market program. The agreement follows the Sharpe Vision agreement announced on January 23, 2024



Two new markets, **Belgium** and **Netherlands**, joined **China** and **Japan** with a **20%+ share of refractive procedures**. Spain, at approximately 18% share, should be the next large market to reach 20% share.

ENGAGED HUNDREDS OF U.S. AND APAC SURGEONS AT INDUSTRY MEETINGS IN MARCH & APRIL

ASCRS Annual Meeting, **Boston** and STAAR APAC Experts Summit, **Okinawa**

- 44 posters and presentations featuring ICL, including at least two that should meaningfully increase surgeon confidence in the measurement of the eye and ICL lens size selection
- Launched STAAR University, our medical science website, at ASCRS for surgeons and other healthcare professionals, featuring clinical data and research, and the ability to apply for grants
- Introduced Stella® ordering and planning system
- 93% of those surveyed “Agreed” or “Strongly Agreed” that, based on the data presented, they were more comfortable recommending EVO ICL for patients -6 and above



Achieved **three million total implantable collamer® lenses (ICLs)** sold in March 2024. >1.5M ICLs have been sold in just the last three years, i.e. fiscal years 2021-2023.

The EVO ICL™ Procedure and Collamer® Material Advantage

30+ Year
History of
Safety and
Effectiveness



Sharp, clear
vision Day &
Night ^{1,2}

Reversible
Lens Implant

99.4%

of EVO patients surveyed would
choose EVO again⁵

200+ Peer-
Reviewed ICL
Clinical Papers



Quick
procedure and
recovery

Additive /
Preserves the
Cornea



3 Million+
Lenses Sold



Does not cause
dry eye
syndrome ^{3,4}

UV Protection

1) Martínez-Plaza E, López-Miguel A, López-de la Rosa A, et al. Effect of the EVO+ Visian Phakic Implantable Collamer Lens on Visual Performance and Quality of Vision and Life, Am J Ophthalmol 2021;226:117-125. 2) Packer M. Evaluation of the EVO/EVO+ Sphere and Toric Visian ICL: Six month results from the United States Food and Drug Administration clinical trial. Clinical Ophthalmology. 2022;16:1541-53. 3) Ganesh S, Brar S, Pawar A. Matched population comparison of visual outcomes and patient satisfaction between 3 modalities for the correction of low to moderate myopic astigmatism. Clin Ophthalmol. 2017;11:1253-1263. 4) Naves J.S, Carracedo G, Cacho-Babillo I, Diadenosine nucleotid measurements as dry-eye score in patients after LASIK and ICL surgery. Presented at American Society of Cataract and Refractive Surgery (ASCRS) 2012. 5) STAAR Survey.


Our Strategic Priorities and Growth Initiatives ...

Strategic Priorities and Growth Initiatives



- 1 Increasing Surgeon Confidence in Measurement of the Eye and Lens Size Selection
- 2 Increasing -6D to -8D Sales Mix
- 3 New Product Innovation
- 4 Growing New and Emerging markets
- 5 Creating a High-Performance Organization


Increasing Surgeon Confidence Globally



STAAR Investments


- Department of Global Professional Education and Training
- Independent Investigator Trials (IIT) and Independent Medical Education (IME)
- STAAR University Medical Affairs Website
- Technical Solutions, e.g., exploring intermediate lens sizes and AI-based lens size selection tools

EVO ICL Movement Down the Diopter Curve*




* The #1 and #2 procedures in each myopia category (extreme, high, moderate, and low) are shown only. The remaining mix may include ICL, SMILE, or LASIK if not shown.

New Product Innovation



STAAR / We Are Making Investments in New and Emerging Markets



Facts and Data


Among the 80 million new MACs [middle-class and affluent consumer], over 70% of this group will be from tier-3 cities and below, making lower-tier cities an increasingly important part of the market... Our research also shows that even during the relatively difficult last few years, Chinese consumers demonstrated a strong desire to trade up and an increased willingness to pay a premium for quality across product categories.

- BCG, The Next Chapter in China's Consumer Story, June 22, 2023

Consider these numbers. The middle class is the fastest-growing major segment of the Indian population in both percentage and absolute terms, rising at 6.3 percent per year between 1995 and 2021. It now represents 31 percent of the population and is expected to be 38 percent by 2031 and 60 percent in 2047.

- Economic Times, How the Middle Class will Play the Hero in India's Rise, July 9, 2023

STAAR / We Are Creating a High-Performance Organization



 **A VITAL FEW STRATEGIC PRIORITIES**

 **THE ORGANIZATION STRUCTURE & TEAM TO EXECUTE**

STAAR / Governance and Leadership

Board of Directors

Arthur Butcher

Stephen C. Farrell

Tom Frinzi

Wei Jiang

Aimee S. Weisner

Elizabeth Yeu, MD

K. Peony Yu, MD

Lilian Zhou, CFA

STAAR Corporate Officers



TOM FRINZI

Chair of the Board,
President and CEO



WARREN FOUST

Chief Operating Officer

PATRICK WILLIAMS

Chief Financial Officer

MAGDA MICHNA, PHD

Chief Clinical, Regulatory
and Medical Affairs Officer

NATHANIEL SISITSKY

General Counsel and Corporate
Secretary

NANCY SABIN

Chief Marketing Officer

KEITH HOLLIDAY, PHD

Chief Technology Officer

SCOTT BARNES, MD

Chief Medical Officer

A person in a red jacket stands on a rocky cliff with arms raised, overlooking a misty forest valley. The scene is captured in a cinematic style with soft lighting and a vast, hazy landscape.

IT'S OUR TIME...
IT'S EVO'S TIME!

 STAARSURGICAL

Appendix ...

Reconciliation of Non-GAAP Financial Measures

Net Income to Adjusted EBITDA (in 000's except for per share data) Unaudited

	Q1-23	Q2-23	Q3-23	Q4-23	2023	Q1-24	2024 Outlook ⁽²⁾
Net income - (as reported)	\$ 2,710	\$ 6,064	\$ 4,817	\$ 7,756	\$ 21,347	\$ (3,339)	\$ -
Provision (benefit) for income taxes	2,009	2,428	1,929	5,983	12,349	1,128	4,500
Other (income) expense, net	(1,919)	105	(451)	(3,334)	(5,599)	(70)	-
Depreciation	1,113	1,285	1,345	1,368	5,111	1,237	4,300
Amortization of intangible assets	7	10	(2)	(2)	13	-	-
Stock-based compensation	6,065	8,423	8,846	182	23,516	6,339	30,300
Adjusted EBITDA	\$ 9,985	\$ 18,315	\$ 16,484	\$ 11,953	\$ 56,737	\$ 5,295	\$ 39,100
<i>Adjusted EBITDA as a % of Revenue</i>	13.6%	19.8%	20.5%	15.7%	17.6%	6.8%	10.5%
Net income per share, diluted- (as reported)	\$ 0.05	\$ 0.12	\$ 0.10	\$ 0.16	\$ 0.43	\$ (0.07)	\$ -
Provision (benefit) for income taxes	0.04	0.05	0.04	0.12	0.25	0.02	0.09
Other (income) expense, net	(0.04)	-	(0.01)	(0.07)	(0.11)	-	-
Depreciation	0.02	0.03	0.03	0.03	0.10	0.03	0.08
Amortization of intangible assets	-	-	-	-	-	-	-
Stock-based compensation	0.12	0.17	0.18	-	0.48	0.13	0.58
Adjusted EBITDA per share, diluted ⁽¹⁾	\$ 0.20	\$ 0.37	\$ 0.33	\$ 0.24	\$ 1.15	\$ 0.11	\$ 0.75
Weighted average shares outstanding - Diluted	49,500	49,516	49,370	49,242	49,427	49,275	52,000

⁽¹⁾ Adjusted EBITDA per diluted share may not add due to rounding

⁽²⁾ 2024 Outlook lines items are all approximations and assumes breakeven Net Income

ICL Sales by Geography

(\$ 000'S) UNAUDITED

ICL Sales by Region ⁽⁵⁾	FISCAL YEAR			THREE MONTHS ENDED				FIRST QUARTER 2024
	2021	2022	2023	March 31, 2023	June 30, 2023	September 29, 2023	December 29, 2023	March 29, 2023
Americas ⁽¹⁾	\$14,054	\$20,114	\$22,233	\$5,566	\$5,954	\$5,449	\$5,264	\$6,260
EMEA ⁽²⁾	\$37,343	\$36,715	\$39,318	\$10,180	\$9,782	\$9,253	\$10,103	\$11,299
APAC ⁽³⁾	\$161,508	\$212,883	\$257,876	\$54,879	\$77,376	\$66,367	\$59,254	\$59,592
Global ICL Sales	\$212,905	\$269,712	\$319,427	\$70,625	\$93,112	\$81,069	\$74,621	\$77,151
Global ICL Sales Growth	51%	27%	18%	20%	19%	13%	22%	9%
Americas ICL Sales Growth								12%
EMEA ICL Sales Growth								11%
APAC ICL Sales Growth								9%
Global ICL Unit Growth	48%	33%	19%	20%	21%	14%	19%	2%

ICL Sales by Country ^(4,5)	FISCAL YEAR			THREE MONTHS ENDED				FIRST QUARTER 2024
	2021	2022	2023	March 31, 2023	June 30, 2023	September 29, 2023	December 29, 2023	March 29, 2023
China	\$107,130	\$147,967	\$185,404	\$35,042	\$61,288	\$48,262	\$40,813	\$38,460
Growth	50%	38%	25%	25%	33%	14%	30%	10%
Japan	\$28,688	\$32,623	\$36,352	\$9,203	\$8,563	\$9,091	\$9,495	\$10,227
Growth	56%	14%	11%	6%	13%	12%	16%	11%
South Korea	\$15,173	\$17,940	\$19,853	\$6,656	\$3,316	\$4,886	\$4,996	\$6,725
Growth	36%	18%	11%	19%	(15)%	1%	39%	1%
United States	\$9,478	\$15,070	\$17,168	\$4,396	\$4,446	\$4,162	\$4,164	\$5,039
Growth	58%	59%	14%	71%	10%	6%	(8)%	15%

Notes:

(1) Americas includes the United States, Canada and Latin American countries

(2) EMEA includes Spain, Germany, United Kingdom, European, Middle East and Africa Distributors


(3) APAC includes China, Japan, South Korea, India and the rest of Asia Pacific distributors

(4) ICL Sales by country includes countries representing more than 5% of total ICL sales in the most recently completed fiscal year

(5) ICL sales do not include IOL, injector or other sales.

STAAR / We Are Using Our Increasing Capabilities and Financial Strength to Outpace the Industry

We are establishing EVO ICL™ as The First Choice for Doctors and Patients Seeking Visual Freedom




⌵
 ICL Grows through
 Transient Macro and
 Business Cycle Headwinds
ICL unit growth...
 +26 points above industry (2023)*
 +28 points above industry (2022)*

* Global ICL unit growth vs. Market Scope global refractive industry procedure growth.

** ICL outperformance = Global ICL unit growth less refractive industry procedure growth.

Current Global Refractive Surgery Market is ~4 Million Procedures Annually


Top 15 Refractive Procedure Markets



* Company estimates as of January 2024.

STAAR / EVO ICL™ Market Share

Estimates as of January 2, 2024 *



* Company estimates based on Market Scope, Refractive Surgery Council and survey data as of January 2, 2024, and estimated global refractive procedure volumes in 2023 of approximately 4.1 million.



EVO ICL is a unique technology. Our market share capture in Japan, China and South Korea is representative of our market share opportunity in every market in which we operate. In every market we have initially faced a variety of obstacles to gain share and add procedures to the refractive market, but we have and continue to work successfully to overcome any obstacles, getting better at doing so over time.

TARGET SALES AND OPERATING MODEL

SALES

Approximately
15%

TO

Approximately
20%

ANNUAL GROWTH RANGE Y/Y

3-Year Sales CAGR (2024-2026)



Approximately
\$500 TO \$550 MILLION

Fiscal 2026
Sales

OPERATING MARGIN

Approximately
12%

TO

Approximately
16%

ANNUAL OPERATING MARGIN

GAAP OPERATING MARGIN (2024-2026)




Approximately
\$60 TO \$90 MILLION

Fiscal 2026
Operating Income

STAAR = 3 Million ICLs and Growing...

TOTAL ICLs SOLD...



STAAR expects to sell more ICLs in the next three years (2024-2026) than the first 25 years of ICL sales combined.



Happy EVO ICL Patients and Surgeons Globally!

